Hedge Fund ADAR1 Capital Management Invests $36 Million in Denali Therapeutics Following FDA Approval
ADAR1 Capital Management disclosed a significant investment of approximately $36.20 million into Denali Therapeutics, acquiring 1,819,339 shares during the first quarter of 2026 following its first FDA approval. The stake now represents 2.12% of ADAR1’s reported equity assets.
Tickers: $DNLI
Topics: ADAR1 Capital Management Denali Therapeutics SEC filing stock purchase